MLICM
OTLK icon

Metropolitan Life Insurance Company (MetLife)’s Outlook Therapeutics OTLK Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-429
Closed -$14.9K – 2434
2023
Q2 		$14.9K Hold
429
– – ﹤0.01% 2087
2023
Q1 		$9.36K Buy
+429
New +$9.6K ﹤0.01% 2185

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OTLK Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 429 shares — an estimated $14.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OTLK in Q1 2023 and held it in 2 quarters. The position peaked at $14.9K in Q2 2023. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 429 Outlook Therapeutics shares in Q3 2023, an estimated $14.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Outlook Therapeutics in Q1 2023 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Outlook Therapeutics position peaked at $14.9K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.